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DOI 10.1016/j.chembiol.2011.11.008In 2009, a small biotech company, Patho-
genica, was founded in Cambridge,
Massachusetts, aimed at applying the
advances made in next-generation DNA
sequencing technology to the clinical
diagnostics arena. Thus, Pathogenica
became one of the first companies poised
to take advantage of the burgeoning
wealth of genomics data by devising clin-
ical testing kits for detecting sample path-
ogens, drug resistance genes, and toxins.
‘‘We have 20 years or more of genomics
research pushing us towards clinical
applications, and a great weight of new
genomics data emerging every week,’’
says Adeyemi Adesokan, Ph.D., Chief
Executive Officer. ‘‘Both patients and
clinicians are now increasingly genomics‘‘Both patients and clinicians are now increasingly genomics
literate and demanding ever more accurate and useful diseases
diagnostics.’’—Adeyemi Adesokan, CEO, Pathogenica.literate and demanding ever more accu-
rate and useful diseases diagnostics.
This combination of drive and demand
is ripe for the correct application. The
new generation of DNA sequencers is
the most accurate tool we have for
disease identification. The technology
has evolved to the point where it can
now be applied in clinical labs’’.
Pathogenica’s non-PCR approach is
a variant of universal molecular inversion
probe (MIP) technology.WithMIP, specific
regions of a target genome are captured
using single-stranded DNA molecules as
probes. The probes are complementary
to the genome target. Their scientists
have performed selective sequencing of
key genomic markers within pathogenic
genomes and developed a library of
probes, called DxSeq probes, for use in
clinical testing. ‘‘We do not sequence the
entire pathogen, just the portions that
are necessary to specifically identify the
organisms, toxins, or drug resistance
genes of interest,’’ explains Alex Rolfe,
Director of Bioinformatics. ‘‘A key advan-tage of this approach in the clinical space
is the optimization of sequencing band-
width for quantitation of target nucleic
acids, rather than sequencing greater
than 99.9% unwanted/nonuseful reads as
might be the case for other approaches.’’
Probes are then deployed in sample
genomic DNA extracted using standard
tissue extraction protocols. If the probes
find a genetic match in the sample,
a definitive diagnosis is made. ‘‘We select
a region of sample DNA with probes that
are homologous to the surrounding
region,’’ explains Rolfe. In many cases,
the sample DNA does not have to be repli-
cated or amplified, such as with qPCR
methods, reducing some of the steps
required with other protocols. Fewersteps hopefully will translate into faster
turnaround time. ‘‘Our DxSeq technology
greatly improves the time taken to turn-
around sequencing results. In combina-
tion with third-generation platforms such
as the Ion Personal Genome Machine
(PGM) Sequencer, we can achieve
greater than 12 hour turnaround from clin-
ical tissue samples,’’ Rolfe adds.
Next-generation sequencing has obvi-
ously been fantastically useful in
academic settings. ‘‘I am excited about
its potential uses for clinicians and
patients,’’ adds Graeme Doran, Chief
Scientific Officer. ‘‘Pathogenica is one of
the first companies really pushing next-
generation sequencing into the clinical
space.’’ While no tests are FDA-approved
yet, Pathogenica currently provides
research use only (RUO) and service-
based products to the research commu-
nity. Its long-term goal is to license and
sell diagnostic kits to hospitals and
commercial clinical testing laboratories.
Some of the initial research leading to
Pathogenica’s probe technology wasChemistry & Biology 18, November 23, 2011 ªdone by Adesokan, while he was a post-
doctoral fellow in the laboratory of Har-
vard Medical School’s George Church,
a member of Pathogenica’s scientific
advisory board.
Lower Cost Multiplex Testing
Molecular DNA sequencing is vastly more
informative and accurate than a culture-
based test. And compared to a qPCR
test or culture sequencing, Pathogenica’s
technology allows highly multiplexed
tests reaching as low as $10 per test. Its
DxSeq probes are designed to detect
multiple strains or species with a single
probe. What gives the testing protocol
extra power is the ability to deploy multi-
plex probe sets that can capture dozens
to hundreds of strains or species in
a single reaction and from a single
sample. ‘‘This efficiency of sample usage
contrasts favorably with other highly
parallel PCR technologies that perform
many individual PCR reactions, but
require a lot more sample to populate
each of these reactions,’’ says Adesokan.
‘‘We can detect multiple pathogens from
one test and adding new pathogens
adds relatively little cost. For qPCR, cost
would scale much more rapidly with the
number of target loci and organisms.’’
‘‘The use of next gen sequencing for
multiplex identification of microorganisms
is a very promising idea,’’ says Timothy
O’Leary, President of the Association
for Molecular Pathology and Deputy
Chief R&D Officer at Veterans Health
Administration. ‘‘In principle, with next
gen sequencing it is possible to look for
many more microorganisms at the same
time and to characterize them and
quantitate them. I think that is very very
interesting and potentially extremely
powerful for something like infectious
disease diagnosis.’’ The ability to multi-
plex thousands of loci simultaneously
gives Pathogenica an advantage in broad
target coverage, while maintaining target
resolution and sensitivity through near
single-molecule nucleic acid sequencing.
Says Adesokan, ‘‘I’m not aware of any2011 Elsevier Ltd All rights reserved 1343
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strengths and perform individual patient
diagnostics in this price range in under
12 hours.’’
PCR has been the reigning molecular
diagnostic technology, thus a comparison
with Pathogenica’s technology is inevi-
table. Adesokan explains that the DxSeq
probes have significantly reduced cross-
reactivity and mispriming, allowing the
multiplexing of thousands of probes in
a single sample lane and a modular
approach to combining probe sets target-
ing different types of pathogen.
Infectious Disease and
Biosurveillance
Pathogenica’s first clinical applications
are for test panels in viral disease including
HPV, HCV, and HIV. ‘‘We like to point
out new highly interesting reports impli-
cating viral infection in as many as 40%
of cancer types,’’ says Doran. The com-
pany is also developing probe panels1344 Chemistry & Biology 18, November 23,for MRSA, respiratory diseases, E. coli,
and food-borne diseases, both for diag-
nostic and surveillance uses. ‘‘Essentially
any pathogen detection problem can
be addressed with sequencing,’’ adds
Doran. ‘‘The core advantages of next
generation sequencing are the breadth of
target coverage (tens of thousands
of loci can be genotyped), unmatched
specificity provided by single-nucleotide
resolution, near single-molecule sensi-
tivity, and accurate population profiling—
which is important in viral quasispecies
analysis or detection of low abundance
tumor-causing mutations.’’
Doran explains that a rapid, low-cost
DNA sequence-based diagnostic tech-
nology would have widespread appeal.
‘‘Our initial utility is in diagnosing, geno-
typing, and detecting pathogenic drug
resistance,’’ he explains. ‘‘All of this
information is useful for influencing a
clinician’s decision-making in terms of
therapeutic strategy.’’2011 ª2011 Elsevier Ltd All rights reservedWhile it grows its clinical application,
Pathogenica is branching out with its
RUO service offerings. In July 2011, the
company teamed with GenomeQuest,
a company that provides data analysis
tools integrating next-generation se-
quencing into everyday data analysis
workflows. ‘‘One specific application is
for human and pathogen marker pro-
filing,’’ adds Doran. ‘‘We partnered with
GenomeQuest to offer their analysis tools
to customers who are interested in tar-
geted sequencing of human loci.’’
While the dynamics of the clinical
diagnostics marketplace are always
changing, the future is likely to include
an expanded portfolio of sequencing-
based products. Pathogenica, as its
name implies, hopes to be among that
first of the next-generation of service
providers.Alice McCarthy (glodog@comcast.net) is a science
writer based in Gloucester, MA.
